tambotatug pelitecan

all catalysts(0)

nothing on the calendar yet

News(3)

• Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
  Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Ca…
  biospace · 5d ago
• Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
  BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new fi…
  biospace · 19d ago
• Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
  MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…
  fiercebiotech · 19d ago